ArticleJournal of chemical information and modeling2024
Transparent Machine Learning Model to Understand Drug Permeability through the Blood-Brain Barrier.
Article in Journal of chemical information and modeling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gaps in AI-Driven Pharmacokinetic Property Prediction for Early Drug Development: A Scoping Review.Journal of chemical information and modeling · 2026Article
- Estimating Permeabilities from Biased Molecular Dynamics with a Green-Kubo Formalism for Transport across the Blood-Brain Barrier.Journal of chemical information and modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barrier (BBB) selectively regulates the passage of chemical compounds into and out of the central nervous system (CNS). As such, understanding the permeability of drug molecules through the BBB is key to treating neurological diseases and evaluating the response of the CNS to medical treatments. Within the last two decades, a diverse portfolio of machine learning (ML) models have been regularly utilized as a tool to predict, and, to a much lesser extent, understand, several functional properties of medicinal drugs, including their propensity to pass through the BBB. However, the most numerically accurate models to date lack in transparency, as they typically rely on complex blends of different descriptors (or features or fingerprints), many of which are not necessarily interpretable in a straightforward fashion. In fact, the "black-box" nature of these models has prevented us from pinpointing any specific design rule to craft the next generation of pharmaceuticals that need to pass (or not) through the BBB. In this work, we have developed a ML model that leverages an uncomplicated, transparent set of descriptors to predict the permeability of drug molecules through the BBB. In addition to its simplicity, our model achieves comparable results in terms of accuracy compared to state-of-the-art models. Moreover, we use a naive Bayes model as an analytical tool to provide further insights into the structure-function relation that underpins the capacity of a given drug molecule to pass through the BBB. Although our results are computational rather than experimental, we have identified several molecular fragments and functional groups that may significantly impact a drug's likelihood of permeating the BBB. This work provides a unique angle to the BBB problem and lays the foundations for future work aimed at leveraging additional transparent descriptors, potentially obtained via bespoke molecular dynamics simulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.